MedTech Innovator Radar Forum April 7-9 Levels Up MedTech Industry’s Most Rigorous Evaluation Platform and Leading Accelerator Program

Key Takeaways

• Radar Forum consolidates multi‑city road tour into single event
• 300 experts evaluate 150 startups from 1,835 applicants
• FDA, CMS, AMA leaders discuss regulation and reimbursement
• 65 startups will enter MTI’s 2026 Market Accelerator
• Alumni have raised $12 billion, launched 500+ products

Pulse Analysis

The shift from a dispersed road‑tour model to a centralized Radar Forum reflects a broader trend in the medtech ecosystem toward efficiency and deeper stakeholder engagement. By gathering 300 vetted experts—from strategic investors to regulators—in one venue, MedTech Innovator creates a high‑signal environment where startups receive targeted, actionable feedback rather than generic pitch exposure. This format not only shortens the evaluation timeline but also aligns early‑stage companies with the precise criteria that drive commercial success, such as clinical viability and real‑world relevance.

Regulatory and reimbursement pathways are often the most formidable hurdles for emerging medical technologies. The presence of FDA’s Center for Devices and Radiological Health director, CMS innovation leaders, and AMA coding officials at the Radar Forum offers startups rare, direct insight into policy shifts, value‑based care models, and coding strategies that can unlock market access. Structured workshops and "Ask the Expert" sessions translate high‑level policy discussions into practical roadmaps, helping companies anticipate payer requirements and streamline product launch strategies.

MedTech Innovator’s track record—over 16,000 applicants, $12 billion in follow‑on funding, and more than 500 products launched—positions the Radar Forum as a catalyst for the next wave of health‑care innovation. By funneling 65 promising ventures into its 2026 U.S. Market Accelerator, MTI not only amplifies signal over volume but also strengthens the broader innovation pipeline, attracting capital and partnership opportunities that can accelerate adoption across hospitals and health systems. This concentrated approach is likely to set a new benchmark for accelerator programs seeking to deliver measurable market impact.